AstraZeneca Boston Consulting Group Matrix
Actionable Strategy Starts Here
AstraZeneca’s BCG Matrix preview highlights which therapeutic areas and franchises are acting as Stars, Cash Cows, Question Marks, or Dogs amid rapid biopharma shifts—spotlighting oncology strength and emerging respiratory assets. This snapshot shows where cash generation fuels R&D and where strategic divestment or investment might be needed. Purchase the full BCG Matrix for quadrant-level placements, data-backed recommendations, and ready-to-use Word and Excel deliverables to guide investment and portfolio decisions.
Stars
Enhertu
Enhertu, AstraZeneca’s premier antibody-drug conjugate (ADC), posted explosive 2025 alliance revenue growth of 38% to about $12.6 billion, cementing a Star profile in the BCG matrix.
By late 2025 Enhertu is the standard of care for HER2-positive and HER2-low metastatic breast cancer after new first-line approvals, driving rapid uptake in the US and EU.
Ongoing heavy investment in trials for gastric and lung cancers keeps R&D spend high, matching the high-growth, high-share Star classification and positioning Enhertu as a future cash generator.
Tezspire
Tezspire is a Star in AstraZeneca’s BCG matrix: severe-asthma biologic sales rose 65% to $1.13 billion in 2025, driving high revenue growth and strong market share.
It differentiates by treating a broad patient pool regardless of eosinophil biomarkers, expanding addressable market versus traditional eosinophilic biologics.
However, Tezspire consumes heavy cash for global marketing and reimbursement against incumbents—pressuring margins and free cash flow in 2025.
If US and Japan adoption trends persist, Tezspire is likely to become a Cash Cow as the severe-asthma market matures.
Ultomiris
Ultomiris grew 16% in 2025 to $1.27 billion in quarterly sales after transitioning many patients from Soliris, securing a leading share in PNH and aHUS rare-disease markets.
Classed as a Star, Ultomiris is gaining new indications and entering major markets like China, requiring sustained R&D and promotion to support growth.
Strong patent protection through the 2030s underpins its leadership in AstraZeneca’s rare-disease portfolio and fuels the company’s 2030 revenue targets.
Imfinzi
Imfinzi is AstraZeneca’s Star in the BCG matrix: it drove a 39% revenue jump to $1.75 billion in Q4 2025 and leads the unresectable Stage III non-small cell lung cancer market while rapidly gaining share in perioperative gastric and biliary tract cancers.
High IO (immuno-oncology) segment growth makes Imfinzi a cash-consuming growth leader; AstraZeneca is funding large combo trials to defend and extend label, keeping it the primary driver of the company’s double-digit oncology growth.
- Q4 2025 revenue: $1.75B (+39%)
- Market leader: unresectable Stage III NSCLC
- Fast share gains: perioperative gastric, biliary cancers
- Requires heavy R&D investment in combos
- Key driver of double-digit oncology growth
Breztri
Breztri, AstraZeneca’s triple-therapy COPD inhaler, is a Star: 2025 sales rose 23% to about $1.2 billion, driven by leading fixed-dose combination (FDC) share in China and expanding US/Europe rollout.
It generates strong cash but high launch and pricing pressures keep it in Stars; sustained investment in triple-threat efficacy data is critical to defend versus other respiratory majors.
- 2025 sales ≈ $1.2B
- 2025 growth +23%
- Leading FDC share in China
- High launch costs & pricing pressure
- Ongoing clinical data investment required
Blockbuster lineup: Enhertu, Imfinzi, Tezspire, Ultomiris, Breztri drive strong 2025 growth
Stars: Enhertu $12.6B (2025, +38%) — first-line HER2+/-; Tezspire $1.13B (+65%) — broad severe asthma; Ultomiris $1.27B (+16%) — PNH/aHUS leader; Imfinzi $1.75B (Q4 2025, +39%) — IO growth; Breztri $1.2B (+23%) — COPD FDC China leader.
| Product | 2025 Rev | Growth | Notes |
|---|---|---|---|
| Enhertu | $12.6B | +38% | First-line HER2+/HER2-low |
| Tezspire | $1.13B | +65% | Broad severe asthma |
| Ultomiris | $1.27B | +16% | PNH/aHUS leader |
| Imfinzi | $1.75B (Q4) | +39% | IO combos, perioperative gains |
| Breztri | $1.2B | +23% | COPD FDC, China lead |
What is included in the product
Detailed Word Document
Comprehensive BCG analysis of AstraZeneca’s portfolio: identifies Stars, Cash Cows, Question Marks, Dogs with strategic invest/hold/divest guidance.
Customizable Excel Spreadsheet
One-page AstraZeneca BCG Matrix placing each business unit in a quadrant for swift portfolio decisions.
Cash Cows
Farxiga
Farxiga, AstraZeneca’s leading SGLT2 inhibitor, delivered over $2.06 billion in Q4 2025 with steady high-single-digit growth, making it a top cash cow.
It holds dominant market share in mature T2D, heart failure, and CKD markets, producing a reliable stream of high-margin cash.
Established indications mean lower promotional spend than oncology, freeing free cash flow for R&D and to support AstraZeneca’s 2025 dividend payments.
Tagrisso
Tagrisso remains the backbone of AstraZeneca’s oncology segment, delivering roughly $1.9 billion in Q4 2025 sales as the established leader in EGFR‑mutated non‑small cell lung cancer.
Growth has stabilized at about 10–12% in mature markets, but high market share and lean manufacturing make it a classic Cash Cow.
Its operating margins are among the highest in the portfolio, funding R&D and expansion into cell therapy programs.
Despite impending patent cliffs, Tagrisso’s current dominance lets AstraZeneca milk substantial cash flow for reinvestment.
Lynparza
Lynparza, the first-in-class PARP inhibitor, generated $878 million in Q4 2025 sales and holds a leading share across ovarian, breast, prostate, and pancreatic cancers via AstraZeneca’s Merck partnership.
Growth slowed to 4% as the PARP market matures, but high share and low capex mean most revenue converts to operating profit, keeping Lynparza a cash cow for AstraZeneca’s oncology franchise.
Calquence
Calquence reached $967 million in Q4 2025 sales and grew 20% year-over-year, securing leadership in front-line CLL; its high market share in a stable therapeutic area marks it as a maturing Star shifting into the Cash Cow quadrant.
The drug delivers steady, high-margin cash flow thanks to an established safety-efficacy profile and strong physician loyalty, funding R&D for next-generation hematology assets in AstraZeneca’s pipeline.
- Q4 2025 sales: $967M
- YoY growth: 20%
- Status: maturing Star → Cash Cow
- Role: funds hematology R&D
- Key strength: high margins, physician loyalty
Fasenra
Fasenra is a mature leader in severe eosinophilic asthma, delivering $530 million in Q4 2025 sales and sustaining a 12% growth rate, marking it as a high-share, low-growth product for AstraZeneca.
Its convenient dosing and proven long-term safety keep strong specialist uptake; market saturation makes it a Cash Cow that generates steady free cash flow with optimized marketing spend.
Fasenra’s cash supports launches like Airsupra and expands AstraZeneca’s immunology portfolio, funding R&D and commercialization without large incremental investment.
- Q4 2025 sales $530 million
- 12% steady growth rate
- High specialist market share
- Funds Airsupra launch and immunology expansion
High‑margin cash engines: Farxiga $2.06B, Tagrisso $1.9B fuel R&D & launches
Farxiga $2.06B Q4 2025; Tagrisso $1.9B; Lynparza $878M; Calquence $967M; Fasenra $530M — high-share, low-growth assets generating strong operating margins and free cash flow to fund R&D, dividends, and new launches.
| Product | Q4 2025 Sales | Growth |
|---|---|---|
| Farxiga | $2.06B | high‑single‑digit |
| Tagrisso | $1.9B | 10–12% |
| Lynparza | $878M | ~4% |
| Calquence | $967M | 20% |
| Fasenra | $530M | 12% |
Preview = Final Product
AstraZeneca BCG Matrix
The file you're previewing is the exact AstraZeneca BCG Matrix report you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready document crafted for strategic clarity and professional use.
Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Actionable Strategy Starts Here
AstraZeneca’s BCG Matrix preview highlights which therapeutic areas and franchises are acting as Stars, Cash Cows, Question Marks, or Dogs amid rapid biopharma shifts—spotlighting oncology strength and emerging respiratory assets. This snapshot shows where cash generation fuels R&D and where strategic divestment or investment might be needed. Purchase the full BCG Matrix for quadrant-level placements, data-backed recommendations, and ready-to-use Word and Excel deliverables to guide investment and portfolio decisions.
Stars
Enhertu
Enhertu, AstraZeneca’s premier antibody-drug conjugate (ADC), posted explosive 2025 alliance revenue growth of 38% to about $12.6 billion, cementing a Star profile in the BCG matrix.
By late 2025 Enhertu is the standard of care for HER2-positive and HER2-low metastatic breast cancer after new first-line approvals, driving rapid uptake in the US and EU.
Ongoing heavy investment in trials for gastric and lung cancers keeps R&D spend high, matching the high-growth, high-share Star classification and positioning Enhertu as a future cash generator.
Tezspire
Tezspire is a Star in AstraZeneca’s BCG matrix: severe-asthma biologic sales rose 65% to $1.13 billion in 2025, driving high revenue growth and strong market share.
It differentiates by treating a broad patient pool regardless of eosinophil biomarkers, expanding addressable market versus traditional eosinophilic biologics.
However, Tezspire consumes heavy cash for global marketing and reimbursement against incumbents—pressuring margins and free cash flow in 2025.
If US and Japan adoption trends persist, Tezspire is likely to become a Cash Cow as the severe-asthma market matures.
Ultomiris
Ultomiris grew 16% in 2025 to $1.27 billion in quarterly sales after transitioning many patients from Soliris, securing a leading share in PNH and aHUS rare-disease markets.
Classed as a Star, Ultomiris is gaining new indications and entering major markets like China, requiring sustained R&D and promotion to support growth.
Strong patent protection through the 2030s underpins its leadership in AstraZeneca’s rare-disease portfolio and fuels the company’s 2030 revenue targets.
Imfinzi
Imfinzi is AstraZeneca’s Star in the BCG matrix: it drove a 39% revenue jump to $1.75 billion in Q4 2025 and leads the unresectable Stage III non-small cell lung cancer market while rapidly gaining share in perioperative gastric and biliary tract cancers.
High IO (immuno-oncology) segment growth makes Imfinzi a cash-consuming growth leader; AstraZeneca is funding large combo trials to defend and extend label, keeping it the primary driver of the company’s double-digit oncology growth.
- Q4 2025 revenue: $1.75B (+39%)
- Market leader: unresectable Stage III NSCLC
- Fast share gains: perioperative gastric, biliary cancers
- Requires heavy R&D investment in combos
- Key driver of double-digit oncology growth
Breztri
Breztri, AstraZeneca’s triple-therapy COPD inhaler, is a Star: 2025 sales rose 23% to about $1.2 billion, driven by leading fixed-dose combination (FDC) share in China and expanding US/Europe rollout.
It generates strong cash but high launch and pricing pressures keep it in Stars; sustained investment in triple-threat efficacy data is critical to defend versus other respiratory majors.
- 2025 sales ≈ $1.2B
- 2025 growth +23%
- Leading FDC share in China
- High launch costs & pricing pressure
- Ongoing clinical data investment required
Blockbuster lineup: Enhertu, Imfinzi, Tezspire, Ultomiris, Breztri drive strong 2025 growth
Stars: Enhertu $12.6B (2025, +38%) — first-line HER2+/-; Tezspire $1.13B (+65%) — broad severe asthma; Ultomiris $1.27B (+16%) — PNH/aHUS leader; Imfinzi $1.75B (Q4 2025, +39%) — IO growth; Breztri $1.2B (+23%) — COPD FDC China leader.
| Product | 2025 Rev | Growth | Notes |
|---|---|---|---|
| Enhertu | $12.6B | +38% | First-line HER2+/HER2-low |
| Tezspire | $1.13B | +65% | Broad severe asthma |
| Ultomiris | $1.27B | +16% | PNH/aHUS leader |
| Imfinzi | $1.75B (Q4) | +39% | IO combos, perioperative gains |
| Breztri | $1.2B | +23% | COPD FDC, China lead |
What is included in the product
Detailed Word Document
Comprehensive BCG analysis of AstraZeneca’s portfolio: identifies Stars, Cash Cows, Question Marks, Dogs with strategic invest/hold/divest guidance.
Customizable Excel Spreadsheet
One-page AstraZeneca BCG Matrix placing each business unit in a quadrant for swift portfolio decisions.
Cash Cows
Farxiga
Farxiga, AstraZeneca’s leading SGLT2 inhibitor, delivered over $2.06 billion in Q4 2025 with steady high-single-digit growth, making it a top cash cow.
It holds dominant market share in mature T2D, heart failure, and CKD markets, producing a reliable stream of high-margin cash.
Established indications mean lower promotional spend than oncology, freeing free cash flow for R&D and to support AstraZeneca’s 2025 dividend payments.
Tagrisso
Tagrisso remains the backbone of AstraZeneca’s oncology segment, delivering roughly $1.9 billion in Q4 2025 sales as the established leader in EGFR‑mutated non‑small cell lung cancer.
Growth has stabilized at about 10–12% in mature markets, but high market share and lean manufacturing make it a classic Cash Cow.
Its operating margins are among the highest in the portfolio, funding R&D and expansion into cell therapy programs.
Despite impending patent cliffs, Tagrisso’s current dominance lets AstraZeneca milk substantial cash flow for reinvestment.
Lynparza
Lynparza, the first-in-class PARP inhibitor, generated $878 million in Q4 2025 sales and holds a leading share across ovarian, breast, prostate, and pancreatic cancers via AstraZeneca’s Merck partnership.
Growth slowed to 4% as the PARP market matures, but high share and low capex mean most revenue converts to operating profit, keeping Lynparza a cash cow for AstraZeneca’s oncology franchise.
Calquence
Calquence reached $967 million in Q4 2025 sales and grew 20% year-over-year, securing leadership in front-line CLL; its high market share in a stable therapeutic area marks it as a maturing Star shifting into the Cash Cow quadrant.
The drug delivers steady, high-margin cash flow thanks to an established safety-efficacy profile and strong physician loyalty, funding R&D for next-generation hematology assets in AstraZeneca’s pipeline.
- Q4 2025 sales: $967M
- YoY growth: 20%
- Status: maturing Star → Cash Cow
- Role: funds hematology R&D
- Key strength: high margins, physician loyalty
Fasenra
Fasenra is a mature leader in severe eosinophilic asthma, delivering $530 million in Q4 2025 sales and sustaining a 12% growth rate, marking it as a high-share, low-growth product for AstraZeneca.
Its convenient dosing and proven long-term safety keep strong specialist uptake; market saturation makes it a Cash Cow that generates steady free cash flow with optimized marketing spend.
Fasenra’s cash supports launches like Airsupra and expands AstraZeneca’s immunology portfolio, funding R&D and commercialization without large incremental investment.
- Q4 2025 sales $530 million
- 12% steady growth rate
- High specialist market share
- Funds Airsupra launch and immunology expansion
High‑margin cash engines: Farxiga $2.06B, Tagrisso $1.9B fuel R&D & launches
Farxiga $2.06B Q4 2025; Tagrisso $1.9B; Lynparza $878M; Calquence $967M; Fasenra $530M — high-share, low-growth assets generating strong operating margins and free cash flow to fund R&D, dividends, and new launches.
| Product | Q4 2025 Sales | Growth |
|---|---|---|
| Farxiga | $2.06B | high‑single‑digit |
| Tagrisso | $1.9B | 10–12% |
| Lynparza | $878M | ~4% |
| Calquence | $967M | 20% |
| Fasenra | $530M | 12% |
Preview = Final Product
AstraZeneca BCG Matrix
The file you're previewing is the exact AstraZeneca BCG Matrix report you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready document crafted for strategic clarity and professional use.
